Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published Date:

Abstract

The lysosomal enzyme glucocerebrosidase-1 (GCase) catalyzes the cleavage of a major glycolipid glucosylceramide into glucose and ceramide. The absence of fully functional GCase leads to the accumulation of its lipid substrates in lysosomes, causing Gaucher disease, an autosomal recessive disorder that displays profound genotype-phenotype nonconcordance. More than 250 disease-causing mutations in , the gene encoding GCase, have been discovered, although only one of these, N370S, causes 70% of disease. Here, we have used a knowledge-based docking protocol that considers experimental data of protein-protein binding to generate a complex between GCase and its known facilitator protein saposin C (SAPC). Multiscale molecular-dynamics simulations were used to study lipid self-assembly, membrane insertion, and the dynamics of the interactions between different components of the complex. Deep learning was applied to propose a model that explains the mechanism of GCase activation, which requires SAPC. Notably, we find that conformational changes in the loops at the entrance of the substrate-binding site are stabilized by direct interactions with SAPC and that the loss of such interactions induced by N370S and another common mutation, L444P, result in destabilization of the complex and reduced GCase activation. Our findings provide an atomistic-level explanation for GCase activation and the precise mechanism through which N370S and L444P cause Gaucher disease.

Authors

  • Raquel Romero
    Department of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom.
  • Arvind Ramanathan
    Biomedical Sciences, Engineering, and Computing Group, Health Data Science Institute, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
  • Tony Yuen
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Debsindhu Bhowmik
    Computational Science and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37830.
  • Mehr Mathew
    Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Lubna Bashir Munshi
    Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Seher Javaid
    Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Madison Bloch
    Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Daria Lizneva
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Alina Rahimova
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Ayesha Khan
    Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Charit Taneja
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Se-Min Kim
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Li Sun
    Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Maria I New
    Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 maria.new@mssm.edu shozeb.haider@ucl.ac.uk mone.zaidi@mssm.edu.
  • Shozeb Haider
    Department of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom; maria.new@mssm.edu shozeb.haider@ucl.ac.uk mone.zaidi@mssm.edu.
  • Mone Zaidi
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; maria.new@mssm.edu shozeb.haider@ucl.ac.uk mone.zaidi@mssm.edu.